NCT07231419招募中3 期
A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of the Efficacy and Safety of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 734
- 试验地点
- 76
- 主要终点
- Change From Baseline in the Weekly Average of Daily Pain Intensity on the Numeric Pain Rating Scale (NPRS) at Week 12 Compared to Placebo
研究概览
简要总结
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine in participants with pain associated with diabetic peripheral neuropathy (DPN).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Body weight greater than or equal to (≥)45 kilogram (kg)
- •Body mass index (BMI) ≥18 to less than (<) 40 kilogram per meter square (kg/m^2)
- •Diagnosis of diabetes mellitus type 1 or type 2 and with glycosylated hemoglobin A1c (HbA1c) ≤9% and the presence of bilateral pain in lower extremities due to DPN for at least 1 year
- •Weekly average of daily NPRS score ≥4 and less than or equal to (≤) 9 with limited variation in the 7-day Baseline Period
排除标准
- •More than 3 missing daily NPRS scores during the 7-day Baseline Period
- •Received Journavx within 30 days of study drug dosing
- •Any sensory abnormality (excluding DPN) as pre-specified in the protocol
- •Other protocol defined Inclusion/Exclusion criteria may apply.
研究组 & 干预措施
Suzetrigine (SUZ)
Experimental
Participants will be randomized to receive SUZ.
干预措施: Suzetrigine (Drug)
Placebo
Placebo Comparator
Participants will be randomized to receive placebo matched to SUZ.
干预措施: Placebo (matched to SUZ) (Drug)
结局指标
主要结局
Change From Baseline in the Weekly Average of Daily Pain Intensity on the Numeric Pain Rating Scale (NPRS) at Week 12 Compared to Placebo
时间窗: From Baseline up to Week 12
次要结局
- Change From Baseline in the Medical Outcomes Study 36-item Short-form Health Status (SF-36v2) Physical Component Summary (PCS) Score at Week 12 Compared to Placebo (Pooled with data from Study VX24-548-110)(From Baseline up to Week 12)
研究者
研究点 (76)
Loading locations...
相似试验
招募中
3 期
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral NeuropathyDiabetic Peripheral Neuropathic PainNCT06628908Vertex Pharmaceuticals Incorporated1,100
进行中（未招募）
3 期
A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has SpreadClear Cell Renal Cell CarcinomaNCT04810078Bristol-Myers Squibb681
已完成
3 期
Fixed-Dose Trial in Early Parkinson's Disease (PD)Parkinson DiseaseNCT04201093AbbVie529
招募中
3 期
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With FibrosisNCT0631816989bio, Inc.1,350
进行中（未招募）
3 期
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's TypeAgitationAlzheimer's Type DementiaNCT05397639Suven Life Sciences Limited375